Live life again
We develop transformative therapies for the elimination of the risk for chronic viral diseases
We strive to improve the quality of life of transplant recipients
Transplantation is intended to give patients their life back, but an infection with cytomegalovirus (CMV) triggered by the transplant conditioning therapy may be devastating to patient outcomes. SYN002 is aimed at improving the life of transplant patients and ensure their ability to enjoy a normal life after transplantation by eliminating the risk of CMV infection in transplant recipients, either by treating the donor organ (ex vivo) prior to transplantation or by treating the recipient after transplantation (in vivo).
We strive to improve the quality of life of transplant recipients
Transplantation is intended to give patients their life back, but an infection with cytomegalovirus (CMV) triggered by the transplant conditioning therapy may be devastating to patient outcomes. SYN002 is aimed at improving the life of transplant patients and ensure their ability to enjoy a normal life after transplantation by eliminating the risk of CMV infection in transplant recipients, either by treating the donor organ (ex vivo) prior to transplantation or by treating the recipient after transplantation (in vivo).
Transplantations give patients a second chance at life
Organ and stem cell donation give seriously ill people a second chance at life. Children and young people return to school, and adults can often resume to work and live life again
Cytomegalovirus can be devastating for transplant recipients
All personal investments and preparations related to getting a transplantation may be lost due to a cytomegalovirus (CMV) infection
We protect the investment in quality of life for transplant recipients
By eliminating CMV infection, Synklino will ensure a fast track back to life for patients, so they can live and enjoy the regained life after their transplantation
What is Cytomegalovirus (CMV)?
Human cytomegalovirus (CMV) is a β-herpesvirus. Like all herpesvirus, CMV establishes life-long latent infection and is found in more than 60% of adults worldwide. There is currently no cure for CMV. Once you have been infected with CMV, the virus establishes latency (dormant state) from where it may re-activate and cause an active lytic infection. Normally, a healthy person’s immune system keeps the virus from causing illness and most people will never know they have CMV.
» I have three pairs of new running shoes and new running clothes to put in the closet. It is my belief that it will be good again when I get a new liver
— (Quote from a patient waiting for a liver transplantation)
Synklino in the news
Oral presentation of late-breaking abstract at the World Transplant Congress (“WTC”) in San Francisco taking place 2-6 August 2025
The presentation will include data on the safety and feasibility of the administration of SYN002 to human kidneys during normothermic machine perfusion (NMP), as well as data on the efficacy of eliminating latently infected cells from the treated kidneys.
Synklino Submits Clinical Trial Application to UK Authorities and Prepares for Phase 1 Study of SYN002
Synklino A/S today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its first-in-human clinical trial of SYN002.